Literature DB >> 17633359

[Analysis on TCM syndrome distribution laws in 319 patients with coronary heart disease].

Huan-Lin Wu1, Xin-Min Ruan, Xiao-Bo Yang.   

Abstract

OBJECTIVE: To study TCM syndrome distribution laws in patients with coronary heart diseases (CHD) by epidemiological investigation.
METHODS: A clinical survey was carried out in 319 inpatients with CHD, whose diagnosis was confirmed by coronary arteriography, in the authors' hospital from January 2004 to December 2004. The TCM syndrome distribution laws were analyzed, and the relationship of coronary arteriographic picture with TCM syndrome elements, common symptoms, pulse and tongue figures, as well as the correlation between syndrome typing and blood-lipid levels were analyzed, too.
RESULTS: Qi deficiency was the most popular syndrome in patients with CHD (87.1%), blood stasis syndrome and phlegm retention syndrome took the second place, accounting for 79.9% and 78.7% respectively. No significant difference was shown in comparison of tongue and pulse figures with the affected branches of coronary artery, the dark-pale tongue with white greasy fur and taut-slippery pulse being the dominance in patients. The blood-lipid levels in patients with various TCM syndrome types were similar, showing insignificant difference.
CONCLUSION: The TCM pathogenesis of CHD takes qi deficiency as the core, blood stasis and phlegm retention as the important pathologic products.

Entities:  

Mesh:

Year:  2007        PMID: 17633359

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

Review 1.  Integrative Western and chinese medicine on coronary heart disease: where is the orientation?

Authors:  Siming Li; Hao Xu
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-19       Impact factor: 2.629

2.  [Fuxinfang improves hypoxia-induced injury of human aortic endothelial cells by regulating c-Fos-NR4A1-p38 pathway].

Authors:  J Xu; J Shi; X Cai; S Huang; G Li; Y Xu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.